Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 4;108(9):djw133.
doi: 10.1093/jnci/djw133. Print 2016 Sep.

Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study

Nitin Ohri  1 , Laura A Dawson  1 , Sunil Krishnan  1 , Jinsil Seong  1 , Jason C Cheng  1 , Shiv K Sarin  1 , Milan Kinkhabwala  1 , Mansoor M Ahmed  1 , Bhadrasain Vikram  1 , C Norman Coleman  1 , Chandan Guha  2
Affiliations
Review

Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study

Nitin Ohri et al. J Natl Cancer Inst. .

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide; its incidence is increasing in the United States. Depending on disease extent and underlying liver status, patients may be treated with local, locoregional, and/or systemic therapy. Recent data indicates that radiotherapy (RT) can play a meaningful role in the management of HCC. Here, we review published experiences using RT for HCC, including the use of radiosensitizers and stereotactic RT. We discuss methods for performing preclinical studies of RT for HCC and biomarkers of response. As a part of the HCC Working Group, an informal committee of the National Cancer Institute's Radiation Research Program, we suggest how RT should be implemented in the management of HCC and identify future directions for the study of RT in HCC.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curve for local control following stereotactic body radiotherapy for hepatocellular carcinoma, based on a recent systematic review ( 41 ). Sample size = 394 lesions. Numbers remaining at risk are listed above the x-axis.
Figure 2.
Figure 2.
Current Barcelona Clinic Liver Classification system and proposed roles for radiotherapy in the management of hepatocellular carcinoma. HCC = hepatocellular carcinoma; PS = performance status; RFA = radiofrequency ablation; RT = radiotherapy; SBRT = stereotactic body radiotherapy; TACE = transarterial chemoembolization.
See this image and copyright information in PMC

References

    1. Ferenci P, Fried M, Labrecque D , et al. . World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective . J Gastrointestin Liver Dis. 2010. ; 19 ( 3 ): 311 – 317 . - PubMed
    1. Jemal A, Bray F, Center MM , et al. . Global cancer statistics . CA Cancer J Clin. 2011. ; 61 ( 2 ): 69 – 90 . - PubMed
    1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 . J Clin Oncol. 2009. ; 27 ( 9 ): 1485 – 1491 . - PMC - PubMed
    1. Davila JA, Duan Z, McGlynn KA , et al. . Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States . J Clin Gastroenterol. 2012. ; 46 ( 1 ): 71 – 77 . - PMC - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V , et al. . Sorafenib in advanced hepatocellular carcinoma . N Engl J Med. 2008. ; 359 ( 4 ): 378 – 390 . - PubMed

Substances